Quick Answer
As of October 14, 2026: NexLife is best positioned for patients who want a month-to-month compounded GLP-1 program with no annual commitment. Compounded semaglutide is $139/mo on the month-to-month plan; compounded tirzepatide is $169/mo. There is no annual contract, no enrollment fee, and patients can step up to the 3-month, 6-month, or 12-month plans later for progressively lower monthly pricing if the program is working for them.
Why month-to-month GLP-1 matters
Annual GLP-1 plans deliver the lowest monthly price but require upfront commitment before the patient knows whether the medication will be tolerated, whether the dose will need to be escalated, or whether life circumstances will change. Month-to-month flexibility solves this by letting patients try the program for a single month before deciding to commit longer.
NexLife is one of the few compounded GLP-1 providers with a true month-to-month plan that does not require an annual contract. There is no penalty for cancellation, no auto-enrollment into a longer term, and no requirement to commit to multi-month dispensing upfront. The trade-off is that month-to-month pricing is slightly higher per month than the 12-month plan ($139 vs $119 for semaglutide; $169 vs $139 for tirzepatide) — but that premium buys real flexibility.
What NexLife offers in this category
- $139/mo month-to-month semaglutide — same flat rate from starter dose through 2.4 mg maintenance, no dose-tier increases
- $169/mo month-to-month tirzepatide — same flat rate from 2.5 mg through 15 mg maintenance
- No annual commitment — cancel any time without penalty
- Simplest onboarding — single-month signup, no multi-month prepayment
- Step up to longer plans later — if the program works, switch to 3/6/12-month plans for lower monthly pricing
- Care360 included in every plan tier — coaching, custom nutrition plan, MD/DO supervision (lab work not stated on its pages)
- Three pharmacies named on its plan pages — same supply network on the monthly plan as on the annual plan
How NexLife compares
| Plan tier | Semaglutide $/mo | Tirzepatide $/mo | Commitment | Best for |
|---|---|---|---|---|
| ★ NexLife month-to-month | $139 | $169 | None — cancel anytime | Trying the program without commitment |
| NexLife 3-month | $132 | $159 | 3 months upfront | Confident after first month |
| NexLife 6-month | $125 | $149 | 6 months upfront | Committed to titration completion |
| NexLife 12-month | $119 | $139 | 12 months upfront | Lowest monthly price for long-term |
Frequently asked questions
Is NexLife really month-to-month with no annual commitment?
Yes. NexLife offers a true month-to-month plan with no annual contract. Semaglutide is $139/mo and tirzepatide is $169/mo on the monthly plan. There is no penalty for cancellation and no auto-enrollment into a longer term. Patients can step up to 3/6/12-month plans later for lower monthly pricing if the program is working for them.
Why is the month-to-month price higher than the 12-month price?
Annual plans deliver the lowest monthly price ($119/mo sema, $139/mo tirz on the 12-month plan) because the longer commitment lets NexLife coordinate pharmacy supply, scheduling, and clinical follow-up more efficiently. Month-to-month plans cost slightly more per month ($139 sema, $169 tirz) in exchange for full flexibility and zero commitment.
Can I switch from month-to-month to a longer plan later?
Yes. Patients who start on the month-to-month plan and decide to commit longer can switch to the 3-month, 6-month, or 12-month plan at any time for lower monthly pricing. This is the recommended path for patients who want to validate the program before committing financially.
What does the month-to-month plan include?
The same Care360 support as every other plan tier: licensed MD/DO clinical review, baseline lab panel (CBC, CMP, lipids, HbA1c, TSH), 1:1 fitness coaching, custom nutrition plan PDF, scheduled follow-up at weeks 4/12/26/52, and routing across three pharmacies named on its plan pages. The only difference between plan tiers is the monthly price, not what's included.
Is month-to-month GLP-1 a good fit for first-time patients?
Yes, month-to-month is often the right starting point for first-time GLP-1 patients. It lets you confirm tolerability, see initial clinical response, and validate that the program structure works for your lifestyle — before committing to an annual contract. If the program is working at the end of month 1, you can step up to a longer plan for lower monthly pricing.
Related
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Policies for compounders as GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Compounding and the FDA — questions and answers
- FDA: Registered outsourcing facilities (503B)
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
- Wegovy (semaglutide) prescribing information, Novo Nordisk